NVS vs. REGN: A Head-to-Head Stock Comparison

Updated on October 3, 2025

Here’s a clear look at NVS and REGN, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Profile

NVS trades as an American Depositary Receipt (ADR), offering U.S. investors a convenient way to access its foreign-listed shares. In contrast, REGN is a standard domestic listing.

Symbol	NVS	REGN
Company Name	Novartis AG	Regeneron Pharmaceuticals, Inc.
Country	Switzerland	United States
GICS Sector	Health Care	Health Care
GICS Industry	Pharmaceuticals	Biotechnology
Market Capitalization	254.99 billion USD	62.50 billion USD
Exchange	NYSE	NasdaqGS
Listing Date	November 7, 1996	April 2, 1991
Security Type	ADR	Common Stock

Historical Performance

This chart compares the performance of NVS and REGN by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.

NVS vs. REGN: Growth of a $10,000 investment over the past one year.

Historical Performance at a Glance

Symbol	NVS	REGN
5-Day Price Return	2.34%	-2.55%
13-Week Price Return	2.27%	7.10%
26-Week Price Return	2.04%	-12.16%
52-Week Price Return	9.24%	-46.08%
Month-to-Date Return	-1.03%	-3.17%
Year-to-Date Return	12.87%	-21.07%
10-Day Avg. Volume	2.80M	1.22M
3-Month Avg. Volume	2.81M	1.13M
3-Month Volatility	18.12%	28.52%
Beta	-0.01	0.30

Profitability

Return on Equity (TTM)

NVS

32.56%

Pharmaceuticals Industry

Max: 38.59%
Q3: 19.84%
Median: 11.85%
Q1: 5.40%
Min: -10.91%

In the upper quartile for the Pharmaceuticals industry, NVS’s Return on Equity of 32.56% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.

REGN

15.11%

Biotechnology Industry

Max: 97.92%
Q3: 11.99%
Median: -19.30%
Q1: -51.29%
Min: -132.03%

In the upper quartile for the Biotechnology industry, REGN’s Return on Equity of 15.11% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.

NVS vs. REGN: A comparison of their Return on Equity (TTM) against their respective Pharmaceuticals and Biotechnology industry benchmarks.

Net Profit Margin (TTM)

NVS

24.90%

Pharmaceuticals Industry

Max: 40.67%
Q3: 19.07%
Median: 12.31%
Q1: 4.50%
Min: -9.91%

A Net Profit Margin of 24.90% places NVS in the upper quartile for the Pharmaceuticals industry, signifying strong profitability and more effective cost management than most of its peers.

REGN

31.37%

Biotechnology Industry

Max: 73.34%
Q3: 18.98%
Median: -12.96%
Q1: -105.72%
Min: -259.82%

A Net Profit Margin of 31.37% places REGN in the upper quartile for the Biotechnology industry, signifying strong profitability and more effective cost management than most of its peers.

NVS vs. REGN: A comparison of their Net Profit Margin (TTM) against their respective Pharmaceuticals and Biotechnology industry benchmarks.

Operating Profit Margin (TTM)

NVS

30.03%

Pharmaceuticals Industry

Max: 45.78%
Q3: 23.14%
Median: 16.68%
Q1: 7.98%
Min: -7.13%

An Operating Profit Margin of 30.03% places NVS in the upper quartile for the Pharmaceuticals industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.

REGN

27.02%

Biotechnology Industry

Max: 78.85%
Q3: 21.90%
Median: -13.30%
Q1: -109.94%
Min: -278.10%

An Operating Profit Margin of 27.02% places REGN in the upper quartile for the Biotechnology industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.

NVS vs. REGN: A comparison of their Operating Profit Margin (TTM) against their respective Pharmaceuticals and Biotechnology industry benchmarks.

Profitability at a Glance

Symbol	NVS	REGN
Return on Equity (TTM)	32.56%	15.11%
Return on Assets (TTM)	13.32%	11.81%
Net Profit Margin (TTM)	24.90%	31.37%
Operating Profit Margin (TTM)	30.03%	27.02%
Gross Profit Margin (TTM)	76.12%	86.46%

Financial Strength

Current Ratio (MRQ)

NVS

0.82

Pharmaceuticals Industry

Max: 4.65
Q3: 2.64
Median: 1.85
Q1: 1.26
Min: 0.78

NVS’s Current Ratio of 0.82 falls into the lower quartile for the Pharmaceuticals industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.

REGN

4.60

Biotechnology Industry

Max: 16.97
Q3: 8.39
Median: 4.11
Q1: 2.64
Min: 0.74

REGN’s Current Ratio of 4.60 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.

NVS vs. REGN: A comparison of their Current Ratio (MRQ) against their respective Pharmaceuticals and Biotechnology industry benchmarks.

Debt-to-Equity Ratio (MRQ)

NVS

0.77

Pharmaceuticals Industry

Max: 1.75
Q3: 0.82
Median: 0.35
Q1: 0.13
Min: 0.00

NVS’s Debt-to-Equity Ratio of 0.77 is typical for the Pharmaceuticals industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

REGN

0.09

Biotechnology Industry

Max: 1.92
Q3: 0.79
Median: 0.12
Q1: 0.00
Min: 0.00

REGN’s Debt-to-Equity Ratio of 0.09 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

NVS vs. REGN: A comparison of their Debt-to-Equity Ratio (MRQ) against their respective Pharmaceuticals and Biotechnology industry benchmarks.

Interest Coverage Ratio (TTM)

NVS

22.55

Pharmaceuticals Industry

Max: 103.95
Q3: 43.60
Median: 9.83
Q1: 2.37
Min: -42.71

NVS’s Interest Coverage Ratio of 22.55 is positioned comfortably within the norm for the Pharmaceuticals industry, indicating a standard and healthy capacity to cover its interest payments.

REGN

243.95

Biotechnology Industry

Max: 72.37
Q3: 1.03
Median: -9.59
Q1: -65.05
Min: -163.11

With an Interest Coverage Ratio of 243.95, REGN demonstrates a superior capacity to service its debt, placing it well above the typical range for the Biotechnology industry. This stems from either robust earnings or a conservative debt load.

NVS vs. REGN: A comparison of their Interest Coverage Ratio (TTM) against their respective Pharmaceuticals and Biotechnology industry benchmarks.

Financial Strength at a Glance

Symbol	NVS	REGN
Current Ratio (MRQ)	0.82	4.60
Quick Ratio (MRQ)	0.62	3.78
Debt-to-Equity Ratio (MRQ)	0.77	0.09
Interest Coverage Ratio (TTM)	22.55	243.95

Growth

Revenue Growth

NVS vs. REGN: A side-by-side comparison of their Revenue Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

EPS Growth

NVS vs. REGN: A side-by-side comparison of their EPS Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

Dividend

Dividend Yield (TTM)

NVS

3.27%

Pharmaceuticals Industry

Max: 7.14%
Q3: 3.45%
Median: 2.17%
Q1: 0.33%
Min: 0.00%

NVS’s Dividend Yield of 3.27% is consistent with its peers in the Pharmaceuticals industry, providing a dividend return that is standard for its sector.

REGN

0.00%

Biotechnology Industry

Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

REGN currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

NVS vs. REGN: A comparison of their Dividend Yield (TTM) against their respective Pharmaceuticals and Biotechnology industry benchmarks.

Dividend Payout Ratio (TTM)

NVS

102.24%

Pharmaceuticals Industry

Max: 199.58%
Q3: 97.17%
Median: 53.47%
Q1: 22.97%
Min: 0.00%

NVS’s Dividend Payout Ratio of 102.24% is in the upper quartile for the Pharmaceuticals industry. This indicates a strong commitment to shareholder returns but also suggests that a smaller portion of earnings is retained for reinvestment compared to many peers.

REGN

0.00%

Biotechnology Industry

Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

REGN has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

NVS vs. REGN: A comparison of their Dividend Payout Ratio (TTM) against their respective Pharmaceuticals and Biotechnology industry benchmarks.

Dividend at a Glance

Symbol	NVS	REGN
Dividend Yield (TTM)	3.27%	0.00%
Dividend Payout Ratio (TTM)	102.24%	0.00%

Valuation

Price-to-Earnings Ratio (TTM)

NVS

17.49

Pharmaceuticals Industry

Max: 45.19
Q3: 27.91
Median: 20.59
Q1: 15.08
Min: 3.79

NVS’s P/E Ratio of 17.49 is within the middle range for the Pharmaceuticals industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.

REGN

13.97

Biotechnology Industry

Max: 40.44
Q3: 39.37
Median: 22.12
Q1: 15.76
Min: 3.48

In the lower quartile for the Biotechnology industry, REGN’s P/E Ratio of 13.97 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.

NVS vs. REGN: A comparison of their Price-to-Earnings Ratio (TTM) against their respective Pharmaceuticals and Biotechnology industry benchmarks.

Price-to-Sales Ratio (TTM)

NVS

4.35

Pharmaceuticals Industry

Max: 8.87
Q3: 4.56
Median: 2.14
Q1: 1.58
Min: 0.11

NVS’s P/S Ratio of 4.35 aligns with the market consensus for the Pharmaceuticals industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.

REGN

4.38

Biotechnology Industry

Max: 92.67
Q3: 41.36
Median: 8.45
Q1: 4.46
Min: 0.97

In the lower quartile for the Biotechnology industry, REGN’s P/S Ratio of 4.38 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.

NVS vs. REGN: A comparison of their Price-to-Sales Ratio (TTM) against their respective Pharmaceuticals and Biotechnology industry benchmarks.

Price-to-Book Ratio (MRQ)

NVS

6.06

Pharmaceuticals Industry

Max: 9.78
Q3: 4.99
Median: 2.48
Q1: 1.53
Min: 0.59

NVS’s P/B Ratio of 6.06 is in the upper tier for the Pharmaceuticals industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.

REGN

1.89

Biotechnology Industry

Max: 22.72
Q3: 10.68
Median: 4.55
Q1: 2.44
Min: 0.59

REGN’s P/B Ratio of 1.89 is in the lower quartile for the Biotechnology industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.

NVS vs. REGN: A comparison of their Price-to-Book Ratio (MRQ) against their respective Pharmaceuticals and Biotechnology industry benchmarks.

Valuation at a Glance

Symbol	NVS	REGN
Price-to-Earnings Ratio (TTM)	17.49	13.97
Price-to-Sales Ratio (TTM)	4.35	4.38
Price-to-Book Ratio (MRQ)	6.06	1.89
Price-to-Free Cash Flow Ratio (TTM)	14.21	17.52